Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer
Gastric Cancer
Explore 281 assets in Gastric Cancer →Floatz Rating
CC44/100
Confidence
Indicative
Sponsor
Taiho Pharmaceutical Co., Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04999761CT.gov AB122 Platform Study | — | Recruiting | — | — | — |
NCT05800418CT.gov Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers | — | Completed | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02572687CT.gov A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastric Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer (this asset) | Taiho Pharmaceutical Co., Ltd. | P1 | CC · 44 |
| Rivoceranib | Jiangsu Hansoh Pharmaceutical Co., Ltd. | P4 | BBB |
| Fluorouracilum | I-Mab Biopharma US Limited | P4 | BB |
| Oxaliplatin | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Irinotecan | Shenzhen Xinhe Biomedical | P4 | BB |
| Capecitabine | I-Mab Biopharma US Limited | P3 | BB |
| Epirubicin | Rondo Therapeutics | P3 | BB |
| Docetaxel | Jiangsu Hansoh Pharmaceutical Co., Ltd. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
+42 more in the Gastric Cancer cohort
Other indications for Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Urothelial Carcinoma | — | P3 | BB · 68 |
| Hepatocellular Carcinoma | — | P3 | BB · 65 |
| Lung Cancer | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer in Gastric Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-vascular-endothelial-growth-factor-receptor-type-vegfr-2-extracellular-domain-human-monoclonal-imc-1121b-gamma-chain-disulphide-with-human-monoclonal-imc-1121b-kappa-chain-dimer-gastric-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →